Vitamin D effects on differentiation and cell cycle

Vitamin D

Volumn , Issue , 2011, Pages 1625-1656

  Studzinski, George P ^a   Gocek, Elzbieta ^b   Danilenko, Michael ^c  

^a RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF WROC AW   (Poland)

^c BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84860459739     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-12-381978-9.10084-8     Document Type: Chapter

References (452)

1. Reed S.I. Control of the G1/S transition. Cancer Surv. 1997, 29:7-23.
2. Coffman F.D., Studzinski G.P. Differentiation-related mechanisms which suppress DNA replication. Exp. Cell Res. 1999, 248:58-73.
3. Sherr C.J. D1 in G2. Cell Cycle 2002, 1:36-38.
4. Vermeulen K., Van Bockstaele D.R., Berneman Z.N. The cell cycle: a review of regulation, deregulation and therapeutic targets in cancer. Cell Prolif. 2003, 36:131-149.
5. Cheng M., Sexl V., Sherr C.J., Roussel M.F. Assembly of cyclin D-dependent kinase and titration of p27Kip1 regulated by mitogen-activated protein kinase kinase (MEK1). Proc. Natl. Acad. Sci. USA 1998, 95:1091-1096.
6. Stein G.S., Lian J.B., Owen T.A. Relationship of cell growth to the regulation of tissue-specific gene expression during osteoblast differentiation. FASEB J. 1990, 4:3111-3123.
7. Lian J.B., Stein G.S., Bortell R., Owen T.A. Phenotype suppression: a postulated molecular mechanism for mediating the relationship of proliferation and differentiation by Fos/Jun interactions at AP-1 sites in steroid responsive promoter elements of tissue-specific genes. J. Cell Biochem. 1991, 45:9-14.
8. Studzinski G.P., Harrison L.E. Differentiation-related changes in the cell cycle traverse. Int. Rev. Cytol. 1999, 189:1-58.
9. 3 precedes the G1/G0 phase cell cycle block. Cell Prolif. 1994, 27:643-654.
10. Studzinski G.P., Rathod B., Wang Q.M., Rao J., Zhang F. Uncoupling of cell cycle arrest from the expression of monocytic differentiation markers in HL60 cell variants. Exp. Cell Res. 1997, 232:376-387.
11. Brown G., Choudhry M.A., Durham J., Drayson M.T., Michell R.H. Monocytically differentiating HL60 cells proliferate rapidly before they mature. Exp. Cell Res. 1999, 253:511-518.
12. 3 or all-trans-retinoic acid. Exp. Cell Res. 2001, 266:126-134.
13. 3-induced differentiation of HL60 cells. J. Cell Biochem. 2001, 80:471-482.
14. 3 involves cell cycle arrest in G1 that is preceded by a transient proliferative burst and an increase in cyclin expression. Blood 1999, 93:2721-2729.
15. 3. Proc. Natl. Acad. Sci. USA 1981, 78:4990-4994.
16. Studzinski G.P., Bhandal A.K., Brelvi Z.S. A system for monocytic differentiation of leukemic cells HL 60 by a short exposure to 1,25-dihydroxycholecalciferol. Proc. Soc. Exp. Biol. Med. 1985, 179:288-295.
17. 3 in the myeloid cell differentiation. Proc. Soc. Exp. Biol. Med. 1989, 191:214-220.
18. 3: differential effects on leukemic cell growth, differentiation, and intestinal calcium absorption. Cancer Res. 1990, 50:6857-6864.
19. Studzinski G.P., McLane J.A., Uskokovic M.R. Signaling pathways for vitamin D-induced differentiation: implications for therapy of proliferative and neoplastic diseases. Crit. Rev. Eukaryot. Gene Expr. 1993, 3:279-312.
20. Gocek E., Studzinski G.P. Vitamin D and differentiation incancer. Crit. Rev. Clin. Lab. Sci. 2009, 46:190-209.
21. 3. Cell Cycle 2009, 8:736-741.
22. 3-induced differentiation of AML cells carrying various mutations. Leuk. Res. 2010, 34:649-657.
23. 3 receptor mRNA in human leukaemia cells HL-60. Cell Prolif. 1991, 24:159-170.
24. 3 on proliferation and differentiation of Caco-2 cells. Endocrinology 1994, 134:1710-1717.
25. 3 in cultured human keratinocytes. Arch. Dermatol. Res. 1997, 289:367-372.
26. 3 receptor (VDR) expression in HC-11 mammary cells: regulation by growth-modulatory agents, differentiation, and Ha-Ras transformation. Breast Cancer Res. Treat 1999, 54:123-133.
27. Gombart A.F., Luong Q.T., Koeffler H.P. Vitamin D compounds: activity against microbes and cancer. Anticancer Res. 2006, 26:2531-2542.
28. 3 and retinoic acid. Exp. Cell Res. 1999, 249:279-290.
29. O'Kelly J., Hisatake J., Hisatake Y., Bishop J., Norman A., Koeffler H.P. Normal myelopoiesis but abnormal T lymphocyte responses in vitamin D receptor knockout mice. J. Clin. Invest. 2002, 109:1091-1099.
30. 2: antitumor activity against leukemia, myeloma, and colon cancer cells. J. Natl. Cancer Inst. 2003, 95:896-905.
31. 3 receptor ablation alters mammary gland morphogenesis. Development 2002, 129:3067-3076.
32. Welsh J. Targets of vitamin D receptor signaling in the mammary gland. J. Bone Miner. Res. 2007, 22(Suppl. 2):V86-90.
33. Valrance M.E., Brunet A.H., Acosta A., Welsh J. Dissociation of growth arrest and CYP24 induction by VDR ligands in mammary tumor cells. J. Cell Biochem. 2007, 101:1505-1519.
34. Costa J.L., Eijk P.P., van de Wiel M.A., ten Berge D., Schmitt F., Narvaez C.J., et al. Anti-proliferative action of vitamin D in MCF7 is still active after siRNA-VDR knock-down. BMC Genomics 2009, 10:499.
35. Barsony J., Prufer K. Vitamin D receptor and retinoid X receptor interactions in motion. Vitam. Horm. 2002, 65:345-376.
36. Gocek E., Kielbinski M., Wylob P., Kutner A., Marcinkowska E. Side-chain modified vitamin D analogs induce rapid accumulation of VDR in the cell nuclei proportionately to their differentiation-inducing potential. Steroids 2008, 73:1359-1366.
37. 3. Endocrinology 1986, 119:1406-1408.
38. Nemere I., Norman A.W. The rapid, hormonally stimulated transport of calcium (transcaltachia). J. Bone Miner. Res. 1987, 2:167-169.
39. 3 stimulates expression and translocation of protein kinase Calpha and Cdelta via a nongenomic mechanism and rapidly induces phosphorylation of a 33-kDa protein in acute promyelocytic NB4 cells. J. Biol. Chem. 1996, 271:16090-16096.
40. 3, involves nuclear vitamin D receptor (nVDR) and non-nVDR-mediated pathways. J. Cell Physiol. 2002, 191:198-207.
41. 3 to increase intracellular calcium and activate protein kinase C in mouse osteoblasts. J. Cell Biochem. 2003, 88:794-801.
42. Haussler M.R., Haussler C.A., Jurutka P.W., Thompson P.D., Hsieh J.C., Remus L.S., et al. The vitamin D hormone and its nuclear receptor: molecular actions and disease states. J. Endocrinol. 1997, 154(Suppl):S57-73.
43. Carlberg C. Molecular basis of the selective activity of vitamin D analogues. J. Cell Biochem. 2003, 88:274-281.
44. 3 receptor: a network of coactivator interactions. Gene 2000, 246:9-21.
45. MacDonald P.N., Baudino T.A., Tokumaru H., Dowd D.R., Zhang C. Vitamin D receptor and nuclear receptor coactivators: crucial interactions in vitamin D-mediated transcription. Steroids 2001, 66:171-176.
46. Lee J.W., Lee Y.C., Na S.Y., Jung D.J., Lee S.K. Transcriptional coregulators of the nuclear receptor superfamily: coactivators and corepressors. Cell Mol. Life Sci. 2001, 58:289-297.
47. Bikle D.D., Tu C.L., Xie Z., Oda Y. Vitamin D regulated keratinocyte differentiation: role of coactivators. J. Cell Biochem. 2003, 88:290-295.
48. Tagami T., Lutz W.H., Kumar R., Jameson J.L. The interaction of the vitamin D receptor with nuclear receptor corepressors and coactivators. Biochem. Biophys. Res. Commun. 1998, 253:358-363.
49. 3 in prostate and breast cancer is suppressed by a mechanism involving histone deacetylation. Recent Results Cancer Res. 2003, 164:83-98.
50. Ueki N., Hayman M.J. Signal-dependent N-CoR requirement for repression by the Ski oncoprotein. J. Biol. Chem. 2003, 278:24858-24864.
51. Mackey S.L., Heymont J.L., Kronenberg H.M., Demay M.B. Vitamin D receptor binding to the negative human parathyroid hormone vitamin D response element does not require the retinoid x receptor. Mol. Endocrinol. 1996, 10:298-305.
52. Russell J., Ashok S., Koszewski N.J. Vitamin D receptor interactions with the rat parathyroid hormone gene: synergistic effects between two negative vitamin D response elements. J. Bone Miner. Res. 1999, 14:1828-1837.
53. Kim M.S., Kondo T., Takada I., Youn M.Y., Yamamoto Y., Takahashi S., et al. DNA demethylation in hormone-induced transcriptional derepression. Nature 2009, 461:1007-1012.
54. 3 receptor. Blood 2001, 98:3290-3300.
55. 3 receptor. Cancer Res. 2002, 62:7050-7058.
56. 2 (a novel, noncalcemic vitamin D analogue), combined with arsenic trioxide, has potent antitumor activity against myeloid leukemia. Cancer Res. 2005, 65:2488-2497.
57. 3 leads to the induced differentiation of the myelomonocytic cell line U937. Genes Dev. 1996, 10:142-153.
58. Audo I., Darjatmoko S.R., Schlamp C.L., Lokken J.M., Lindstrom M.J., Albert D.M., et al. Vitamin D analogues increase p53, p21, and apoptosis in a xenograft model of human retinoblastoma. Invest. Ophthalmol. Vis. Sci. 2003, 44:4192-4199.
59. 3 and its analogs. Acta Otolaryngol. 2004, 124:90-96.
60. 3 in human leukemia HL60 cells through a vitamin D response element in the 5'-flanking region. Oncogene 2006, 25:7078-7085.
61. 3 and is required for optimal cell differentiation. Exp. Cell Res. 2007, 313:3034-3045.
62. 3-induced myeloid cell differentiation is regulated by a vitamin D receptor-phosphatidylinositol 3-kinase signaling complex. J. Exp. Med. 1999, 190:1583-1594.
63. 3 regulation of chick myoblast proliferation and differentiation. Mol. Cell Endocrinol. 1999, 153:39-45.
64. Wang X., Studzinski G.P. Phosphorylation of raf-1 by kinase suppressor of ras is inhibited by "MEK-specific" inhibitors PD 098059 and U0126 in differentiating HL60 cells. Exp. Cell Res. 2001, 268:294-300.
65. 3 analogue KH1060 and the phorbol ester TPA. Cancer Lett. 2002, 186:67-74.
66. 3-induced differentiation in human osteoblasts. Immunopharmacol. Immunotoxicol. 2002, 24:31-41.
67. 3 stimulates activator protein 1 DNA-binding activity by a phosphatidylinositol 3-kinase/Ras/MEK/extracellular signal regulated kinase 1/2 and c-Jun N-terminal kinase 1-dependent increase in c-Fos, Fra1, and c-Jun expression in human keratinocytes. J. Invest. Dermatol. 2003, 120:561-570.
68. 3. J. Cell Biochem. 2003 Jun, 89:1087-1101.
69. Wang Q., Harrison J.S., Uskokovic M., Kutner A., Studzinski G.P. Translational study of vitamin D differentiation therapy of myeloid leukemia: effects of the combination with a p38 MAPK inhibitor and an antioxidant. Leukemia 2005, 19:1812-1817.
70. 3 and participates in its anti-apoptotic effect and cell cycle control in differentiating HL60 cells. Cell Cycle 2006, 5:447-451.
71. 2+-dependent protein kinase activity and protein phosphorylation patterns in the differentiation of human promyelocytic leukemia cell line HL-60. Cancer Res. 1985, 45:5159-5164.
72. Todd R.F., Bury M.J., Alvarez P.A., Brott D.A., Liu D.Y. Regulation of human monocyte surface antigen expression. I. Up-modulation of Mo3e antigen expression on U-937 and HL-60 cells stimulated by pharmacologic activators of protein kinase C. Blood 1986, 68:1154-1161.
73. 3 enhances phorbol ester-stimulated differentiation and protein kinase C-dependent substrate phosphorylation activity in the U937 human monoblastoid cell. Endocrinology 1987, 121:1654-1661.
74. Martell R.E., Simpson R.U., Hsu T. Effects of protein kinase inhibitors 1(5-isoquinolinesulfonyl)-2-methylpiperazine dihydrochloride (H-7) and N-[2-guanidinoethyl]-5-isoquinolinesulfonamide hydrochloride (HA1004) on calcitriol-induced differentiation of HL-60 cells. Biochem. Pharmacol. 1988, 37:635-640.
75. 3-induced regulation of protein kinase C gene expression during HL-60 cell differentiation. Cell Growth Differ. 1991, 2:187-194.
76. 3 regulation of phorbol ester receptors in HL-60 leukemia cells. J. Biol. Chem. 1987, 262:5570-5575.
77. 3 in HL-60 cells. J. Biol. Chem. 1990, 265:2370-2374.
78. Gamard C.J., Blobe G.C., Hannun Y.A., Obeid L.M. Specific role for protein kinase C beta in cell differentiation. Cell Growth Differ. 1994, 5:405-409.
79. 3, phospholipase D and protein kinase C in keratinocyte differentiation. Mol. Cell Endocrinol. 2001, 177:173-182.
80. Wali R.K., Baum C.L., Sitrin M.D., Bolt M.J., Dudeja P.K., Brasitus T.A. Effect of vitamin D status on the rapid actions of 1,25-dihydroxycholecalciferol in rat colonic membranes. Am. J. Physiol. 1992, 262:G945-953.
81. + exchange by stimulating membrane phosphoinositide turnover and increasing cytosolic calcium in CaCo-2 cells. Endocrinology 1992, 131:1125-1133.
82. 3. J. Cell Physiol. 1997, 172:284-295.
83. i. Am. J. Physiol. 1994, 267:G465-475.
84. 3 induced activation and subsequent nuclear translocation of MAPK is upstream regulated by PKC in HL-60 cells. Biochem. Biophys. Res. Commun. 1997, 241:419-426.
85. 3 receptor. Endocrinology 1992, 130:2259-2266.
86. 3 receptors synergistically in rat osteosarcoma cells. Mol. Cell Endocrinol. 1994, 101:159-165.
87. 3 receptors by parathyroid hormone in osteoblastic cells: role of second messenger pathways. Endocrinology 1995, 136:705-712.
88. Khan A.A., Dragt B.S., Porte R.J., Groothuis G.M. Regulation of VDR expression in rat and human intestine and liver-consequences for CYP3A expression. Toxicol. Vitro 2010, 24:822-829.
89. Gocek E., Kielbinski M., Marcinkowska E. Activation of intracellular signaling pathways is necessary for an increase in VDR expression and its nuclear translocation. FEBS Lett. 2007, 581:1751-1757.
90. Marcinkowska E., Wiedlocha A., Radzikowski C. Evidence that phosphatidylinositol 3-kinase and p70S6K protein are involved in differentiation of HL-60 cells induced by calcitriol. Anticancer Res. 1998, 18:3507-3514.
91. Liu Q., Ning W., Dantzer R., Freund G.G., Kelley K.W. Activation of protein kinase C-zeta and phosphatidylinositol 3'-kinase and promotion of macrophage differentiation by insulin-like growth factor-I. J. Immunol. 1998, 160:1393-1401.
92. 3 induces biphasic NF-kappaB responses during HL-60 leukemia cells differentiation through protein induction and PI3K/Akt-dependent phosphorylation/degradation of IkappaB. Exp. Cell Res. 2007, 313:1722-1734.
93. 3-induced leukemia cell functional differentiation via Raf/MEK/ERK MAPK signaling. Eur. J. Cell. Biol. 2009, 88:103-115.
94. Alagbala A.A., Johnson C.S., Trump D.L., Posner G.H., Foster B.A. Antitumor effects of two less-calcemic vitamin D analogs (paricalcitol and QW-1624F2-2) in squamous cell carcinoma cells. Oncology 2006, 70:483-492.
95. Lee H.J., So J.Y., Decastro A., Smolarek A., Paul S., Maehr H., et al. Gemini vitamin D analog suppresses ErbB2-positive mammary tumor growth via inhibition of ErbB2/AKT/ERK signaling. J. Steroid Biochem. Mol. Biol. 2010, 121:408-412.
96. 3 in musculoskeletal cells. Steroids 2002, 67:421-427.
97. 3 activate three MAPK pathways and upregulate pRb expression in differentiating HL60 cells. Cell Cycle 2002, 1:410-415.
98. Pouyssegur J., Volmat V., Lenormand P. Fidelity and spatio-temporal control in MAP kinase (ERKs) signalling. Biochem. Pharmacol. 2002, 64:755-763.
99. Strniskova M., Barancik M., Ravingerova T. Mitogen-activated protein kinases and their role in regulation of cellular processes. Gen. Physiol. Biophys. 2002, 21:231-255.
100. Johnson G.L., Lapadat R. Mitogen-activated protein kinase pathways mediated by ERK, JNK, and p38 protein kinases. Science 2002, 298:1911-1912.
101. Chang F., Steelman L.S., Lee J.T., Shelton J.G., Navolanic P.M., Blalock W.L., et al. Signal transduction mediated by the Ras/Raf/MEK/ERK pathway from cytokine receptors to transcription factors: potential targeting for therapeutic intervention. Leukemia 2003, 17:1263-1293.
102. Studzinski G.P., Wang X., Ji Y., Wang Q., Zhang Y., Kutner A., et al. The rationale for deltanoids in therapy for myeloid leukemia: role of KSR-MAPK-C/EBP pathway. J. Steroid Biochem. Mol. Biol. 2005, 97:47-55.
103. Kornfeld K., Hom D.B., Horvitz H.R. The ksr-1 gene encodes a novel protein kinase involved in Ras-mediated signaling in C. elegans. Cell 1995, 83:903-913.
104. Sundaram M., Han M. The C. elegans ksr-1 gene encodes a novel Raf-related kinase involved in Ras-mediated signal transduction. Cell 1995, 83:889-901.
105. Stewart S., Sundaram M., Zhang Y., Lee J., Han M., Guan K.L. Kinase suppressor of Ras forms a multiprotein signaling complex and modulates MEK localization. Mol. Cell Biol. 1999, 19:5523-5534.
106. Zhang Y., Yao B., Delikat S., Bayoumy S., Lin X.H., Basu S., et al. Kinase suppressor of Ras is ceramide-activated protein kinase. Cell 1997, 89:63-72.
107. Xing H.R., Kolesnick R. Kinase suppressor of Ras signals through Thr269 of c-Raf-1. J. Biol. Chem. 2001, 276:9733-9741.
108. Zafrullah M., Yin X., Haimovitz-Friedman A., Fuks Z., Kolesnick R. Kinase suppressor of Ras transphosphorylates c-Raf-1. Biochem. Biophys. Res. Commun. 2009, 390:434-440.
109. Morrison D.K. KSR: a MAPK scaffold of the Ras pathway?. J. Cell Sci. 2001, 114:1609-1612.
110. McKay M.M., Ritt D.A., Morrison D.K. Signaling dynamics of the KSR1 scaffold complex. Proc. Natl. Acad. Sci. USA 2009, 106:11022-11027.
111. 3. J. Cell Physiol. 2004, 198:333-342.
112. Liu L., Channavajhala P.L., Rao V.R., Moutsatsos I., Wu L., Zhang Y., et al. Proteomic characterization of the dynamic KSR-2 interactome, a signaling scaffold complex in MAPK pathway. Biochim. Biophys. Acta 2009, 1794:1485-1495.
113. 3 in promyelocytic NB4 leukemia cells: a structure-function study. Endocrinology 1998, 139:457-465.
114. 3 in normal human keratinocytes. J. Invest. Dermatol. 1996, 106:1212-1217.
115. 3 stimulates activator protein-1-dependent Caco-2 cell differentiation. J. Biol. Chem. 1999, 274:35505-35513.
116. Marcinkowska E. Evidence that activation of MEK1,2/erk1,2 signal transduction pathway is necessary for calcitriol-induced differentiation of HL-60 cells. Anticancer Res. 2001, 21:499-504.
117. 3 in HL60 cells. Cancer Res. 1996, 56:264-267.
118. Solomon C., Kremer R., White J.H., Rhim J.S. Vitamin D resistance in RAS-transformed keratinocytes: mechanism and reversal strategies. Radiat. Res. 2001, 155:156-162.
119. 3-induced differentiation of human leukemia HL60 cells. Exp. Cell Res. 2000, 258:425-437.
120. Wang X., Studzinski G.P. Inhibition of p38MAP kinase potentiates the JNK/SAPK pathway and AP-1 activity in monocytic but not in macrophage or granulocytic differentiation of HL60 cells. J. Cell Biochem. 2001, 82:68-77.
121. Ravid A., Rubinstein E., Gamady A., Rotem C., Liberman U.A., Koren R. Vitamin D inhibits the activation of stress-activated protein kinases by physiological and environmental stresses in keratinocytes. J. Endocrinol. 2002, 173:525-532.
122. Li X., Udagawa N., Itoh K., Suda K., Murase Y., Nishihara T., et al. p38 MAPK-mediated signals are required for inducing osteoclast differentiation but not for osteoclast function. Endocrinology 2002, 143:3105-3113.
123. 3 analog EB1089 induces apoptosis via a p53-independent mechanism involving p38 MAP kinase activation and suppression of ERK activity in B-cell chronic lymphocytic leukemia cells in vitro. Blood 2003, 101:2454-2460.
124. Nonn L., Peng L., Feldman D., Peehl D.M. Inhibition of p38 by vitamin D reduces interleukin-6 production in normal prostate cells via mitogen-activated protein kinase phosphatase 5: implications for prostate cancer prevention by vitamin D. Cancer Res. 2006, 66:4516-4524.
125. Zhang J., Posner G.H., Danilenko M., Studzinski G.P. Differentiation-inducing potency of the seco-steroid JK-1624F2-2 can be increased by combination with an antioxidant and a p38MAPK inhibitor which upregulates the JNK pathway. J. Steroid Biochem. Mol. Biol. 2007, 105:140-149.
126. 3 in leukemia cells but does not promote elevation of basal levels of intracellular calcium. Cancer Res. 2003, 63:1325-1332.
127. Chen-Deutsch X., Garay E., Zhang J., Harrison J.S., Studzinski G.P. c-Jun N-terminal kinase 2 (JNK2) antagonizes the signaling of differentiation by JNK1 in human myeloid leukemia cells resistant to vitamin D. Leuk. Res. 2009, 33:1372-1378.
128. 3-induced growth inhibition. J. Biol. Chem. 2002, 277:25884-25892.
129. Chen F., Studzinski G.P. Expression of the neuronal cyclin-dependent kinase 5 activator p35Nck5a in human monocytic cells is associated with differentiation. Blood 2001, 97:3763-3767.
130. 3-treated HL60 cells. Exp. Cell Res. 1999, 249:422-428.
131. Chen F., Rao J., Studzinski G.P. Specific association of increased cyclin-dependent kinase 5 expression with monocytic lineage of differentiation of human leukemia HL60 cells. J. Leukoc. Biol. 2000, 67:559-566.
132. Studzinski G.P., Garay E., Patel R., Zhang J., Wang X. Vitamin D receptor signaling of monocytic differentiation in human leukemia cells: role of MAPK pathways in transcription factor activation. Curr. Top. Med. Chem. 2006, 6:1267-1271.
133. Studzinski G.P., Harrison J.S. The neuronal cyclin-dependent kinase 5 activator p35Nck5a and Cdk5 activity in monocytic cells. Leuk. Lymphoma 2003, 44:235-240.
134. Harada T., Morooka T., Ogawa S., Nishida E. ERK induces p35, a neuron-specific activator of Cdk5, through induction of Egr1. Nat. Cell Biol. 2001, 3:453-459.
135. 3 contributes to increased expression of p35 activator of cyclin-dependent kinase 5 and consequent onset of the terminal phase of HL60 cell differentiation. Cancer Res. 2004, 64:5425-5433.
136. 3 receptor and other nonreceptor transcription factors. Mol. Endocrinol. 1994, 8:1593-1604.
137. 3. Oncogene 2004, 23:4856-4861.
138. Karin M., Liu Z., Zandi E. AP-1 function and regulation. Curr. Opin. Cell Biol. 1997, 9:240-246.
139. Shaulian E., Karin M. AP-1 in cell proliferation and survival. Oncogene 2001, 20:2390-2400.
140. Sherman M.L., Stone R.M., Datta R., Bernstein S.H., Kufe D.W. Transcriptional and post-transcriptional regulation of c-jun expression during monocytic differentiation of human myeloid leukemic cells. J. Biol. Chem. 1990, 265:3320-3323.
141. 3. Cancer Res. 2006, 66:4402-4409.
142. Owen T.A., Bortell R., Yocum S.A., Smock S.L., Zhang M., Abate C., et al. Coordinate occupancy of AP-1 sites in the vitamin D-responsive and CCAAT box elements by Fos-Jun in the osteocalcin gene: model for phenotype suppression of transcription. Proc. Natl. Acad. Sci. USA 1990, 87:9990-9994.
143. Schule R., Umesono K., Mangelsdorf D.J., Bolado J., Pike J.W., Evans R.M. Jun-Fos and receptors for vitamins A and D recognize a common response element in the human osteocalcin gene. Cell 1990, 61:497-504.
144. Lu B., Rothnagel J.A., Longley M.A., Tsai S.Y., Roop D.R. Differentiation-specific expression of human keratin 1 is mediated by a composite AP-1/steroid hormone element. J. Biol. Chem. 1994, 269:7443-7449.
145. 3-mediated induction. J. Biol. Chem. 2000, 275:47-55.
146. 3-resistant HL60 cells is preceded by reduced growth factor dependence and constitutive up-regulation of Sp1 and AP-1 transcription factors. Cancer Res. 1996, 56:5513-5521.
147. 3 reduces impairment of human osteoblast functions during cellular aging in culture. J. Cell Physiol. 2001, 186:298-306.
148. 3 antiproliferative actions involve vitamin D receptor-mediated activation of MAPK pathways and AP-1/p21(waf1) upregulation in human osteosarcoma. Cancer Lett. 2007, 254:75-86.
149. Bikle D.D., Ng D., Tu C.L., Oda Y., Xie Z. Calcium- and vitamin D-regulated keratinocyte differentiation. Mol. Cell Endocrinol. 2001, 177:161-171.
150. 3. J. Invest. Dermatol. 2002, 119:1109-1113.
151. 3 in induction of leukemia HL60 cell differentiation through the JNK/AP-1/Egr-1 pathway. J. Cell Physiol. 2005, 204:964-974.
152. Dynan W.S., Tjian R. Isolation of transcription factors that discriminate between different promoters recognized by RNA polymerase II. Cell 1983, 32:669-680.
153. Gidoni D., Dynan W.S., Tjian R. Multiple specific contacts between a mammalian transcription factor and its cognate promoters. Nature 1984, 312:409-413.
154. Ikeda K., Nagano K., Kawakami K. Anomalous interaction of Sp1 and specific binding of an E-box-binding protein with the regulatory elements of the Na, K-ATPase alpha 2 subunit gene promoter. Eur. J. Biochem. 1993, 218:195-204.
155. Dusing M.R., Wiginton D.A. Sp1 is essential for both enhancer-mediated and basal activation of the TATA-less human adenosine deaminase promoter. Nucleic Acids Res. 1994, 22:669-677.
156. Lu J., Lee W., Jiang C., Keller E.B. Start site selection by Sp1 in the TATA-less human Ha-ras promoter. J. Biol. Chem. 1994, 269:5391-5402.
157. Rao J., Zhang F., Donnelly R.J., Spector N.L., Studzinski G.P. Truncation of Sp1 transcription factor by myeloblastin in undifferentiated HL60 cells. J. Cell Physiol. 1998, 175:121-128.
158. 3. J. Immunol. 1994, 153:3276-3284.
159. 3 differentially affect hematopoietic transcription factors to induce monocytic differentiation. Int. J. Oncol. 2007, 30:349-355.
160. Chen H.M., Pahl H.L., Scheibe R.J., Zhang D.E., Tenen D.G. The Sp1 transcription factor binds the CD11b promoter specifically in myeloid cells in vivo and is essential for myeloid-specific promoter activity. J. Biol. Chem. 1993, 268:8230-8239.
161. 3 in the p27(Kip1) gene promoter that lacks vitamin D response elements. J. Biol. Chem. 1999, 274:32309-32317.
162. 3-induced monocytic differentiation of HL60 cells. Cancer Res. 2004, 64:370-377.
163. 3. Exp. Cell Res. 2006, 312:2054-2065.
164. Park B.H., Qiang L., Farmer S.R. Phosphorylation of C/EBPbeta at a consensus extracellular signal-regulated kinase/glycogen synthase kinase 3 site is required for the induction of adiponectin gene expression during the differentiation of mouse fibroblasts into adipocytes. Mol. Cell Biol. 2004, 24:8671-8680.
165. Buck M., Poli V., Hunter T., Chojkier M. C/EBPbeta phosphorylation by RSK creates a functional XEXD caspase inhibitory box critical for cell survival. Mol. Cell 2001, 8:807-816.
166. Pan Z., Hetherington C.J., Zhang D.E. CCAAT/enhancer-binding protein activates the CD14 promoter and mediates transforming growth factor beta signaling in monocyte development. J. Biol. Chem. 1999, 274:23242-23248.
167. Pardee A.B. G1 events and regulation of cell proliferation. Science 1989, 246:603-608.
168. Nurse P. Universal control mechanism regulating onset of M-phase. Nature 1990, 344:503-508.
169. Sherr C.J. G1 phase progression: cycling on cue. Cell 1994, 79:551-555.
170. Zhou B.B., Elledge S.J. The DNA damage response: putting checkpoints in perspective. Nature 2000, 408:433-439.
171. Boye E., Skjolberg H.C., Grallert B. Checkpoint regulation of DNA replication. Methods Mol. Biol. 2009, 521:55-70.
172. Peng C.Y., Graves P.R., Thoma R.S., Wu Z., Shaw A.S., Piwnica-Worms H. Mitotic and G2 checkpoint control: regulation of 14-3-3 protein binding by phosphorylation of Cdc25C on serine-216. Science 1997, 277:1501-1505.
173. Mailand N., Podtelejnikov A.V., Groth A., Mann M., Bartek J., Lukas J. Regulation of G2/M events by Cdc25A through phosphorylation-dependent modulation of its stability. EMBO J. 2002, 21:5911-5920.
174. Reinhardt H.C., Yaffe M.B. Kinases that control the cell cycle in response to DNA damage: Chk1, Chk2, and MK2. Curr. Opin. Cell Biol. 2009, 21:245-255.
175. Elledge S.J. Cell cycle checkpoints: preventing an identity crisis. Science 1996, 274:1664-1672.
176. Dou Q.P., Levin A.H., Zhao S., Pardee A.B. Cyclin E and cyclin A as candidates for the restriction point protein. Cancer Res. 1993, 53:1493-1497.
177. Giacinti C., Giordano A. RB and cell cycle progression. Oncogene 2006, 25:5220-5227.
178. Talluri S., Isaac C.E., Ahmad M., Henley S.A., Francis S.M., Martens A.L., et al. A G1 checkpoint mediated by the retinoblastoma protein that is dispensable in terminal differentiation but essential for senescence. Mol. Cell Biol. 2010, 30:948-960.
179. O'Connor P.M., Fan S. DNA damage checkpoints: implications for cancer therapy. Prog. Cell Cycle. Res. 1996, 2:165-173.
180. Hunter T., Pines J. Cyclins and cancer. II: Cyclin D and CDK inhibitors come of age. Cell 1994, 79:573-582.
181. Morgan D.O. Principles of CDK regulation. Nature 1995, 374:131-134.
182. Hoyt M.A. Eliminating all obstacles: regulated proteolysis in the eukaryotic cell cycle. Cell 1997, 91:149-151.
183. Matsuoka M., Kato J.Y., Fisher R.P., Morgan D.O., Sherr C.J. Activation of cyclin-dependent kinase 4 (cdk4) by mouse MO15-associated kinase. Mol. Cell Biol. 1994, 14:7265-7275.
184. Sheaff R.J. Regulation of mammalian cyclin-dependent kinase 2. Methods. Enzymol. 1997, 283:173-193.
185. Bartkova J., Zemanova M., Bartek J. Expression of CDK7/CAK in normal and tumor cells of diverse histogenesis, cell-cycle position and differentiation. Int. J. Cancer 1996, 66:732-737.
186. Jinno S., Suto K., Nagata A., Igarashi M., Kanaoka Y., Nojima H., et al. Cdc25A is a novel phosphatase functioning early in the cell cycle. EMBO J. 1994, 13:1549-1556.
187. Gautier J., Solomon M.J., Booher R.N., Bazan J.F., Kirschner M.W. cdc25 is a specific tyrosine phosphatase that directly activates p34cdc2. Cell 1991, 67:197-211.
188. Heald R., McLoughlin M., McKeon F. Human wee1 maintains mitotic timing by protecting the nucleus from cytoplasmically activated Cdc2 kinase. Cell 1993, 74:463-474.
189. Giles N., Forrest A., Gabrielli B. 14-3-3 acts as an intramolecular bridge to regulate cdc25B localization and activity. J. Biol. Chem. 2003, 278:28580-28587.
190. Matsuoka S., Huang M., Elledge S.J. Linkage of ATM to cell cycle regulation by the Chk2 protein kinase. Science 1998, 282:1893-1897.
191. Besson A., Dowdy S.F., Roberts J.M. CDK inhibitors: cell cycle regulators and beyond. Dev. Cell 2008, 14:159-169.
192. el-Deiry W.S., Tokino T., Velculescu V.E., Levy D.B., Parsons R., Trent J.M., et al. WAF1, a potential mediator of p53 tumor suppression. Cell 1993, 75:817-825.
193. Jiang H., Lin J., Su Z.Z., Collart F.R., Huberman E., Fisher P.B. Induction of differentiation in human promyelocytic HL-60 leukemia cells activates p21, WAF1/CIP1, expression in the absence of p53. Oncogene 1994, 9:3397-3406.
194. Wang Z., Lee H.J., Chai Y., Hu H., Wang L., Zhang Y., et al. Persistent p21Cip1 induction mediates G1 cell cycle arrest by methylseleninic acid in DU145 prostate cancer cells. Curr. Cancer Drug Targets 2010, 10:307-318.
195. Waga S., Hannon G.J., Beach D., Stillman B. The p21 inhibitor of cyclin-dependent kinases controls DNA replication by interaction with PCNA. Nature 1994, 369:574-578.
196. Li D.Q., Pakala S.B., Reddy S.D., Ohshiro K., Peng S.H., Lian Y., et al. Revelation of p53-independent function of MTA1 in DNA damage response via modulation of the p21 WAF1-proliferating cell nuclear antigen pathway. J. Biol. Chem. 2010, 285:10044-10052.
197. Polyak K., Kato J.Y., Solomon M.J., Sherr C.J., Massague J., Roberts J.M., et al. p27Kip1, a cyclin-Cdk inhibitor, links transforming growth factor-beta and contact inhibition to cell cycle arrest. Genes Dev. 1994, 8:9-22.
198. Sheaff R.J., Groudine M., Gordon M., Roberts J.M., Clurman B.E. Cyclin E-CDK2 is a regulator of p27Kip1. Genes Dev. 1997, 11:1464-1478.
199. Tsvetkov L.M., Yeh K.H., Lee S.J., Sun H., Zhang H. p27(Kip1) ubiquitination and degradation is regulated by the SCF(Skp2) complex through phosphorylated Thr187 in p27. Curr. Biol. 1999, 9:661-664.
200. Carrano A.C., Eytan E., Hershko A., Pagano M. SKP2 is required for ubiquitin-mediated degradation of the CDK inhibitor p27. Nat. Cell Biol. 1999, 1:193-199.
201. Hara T., Kamura T., Nakayama K., Oshikawa K., Hatakeyama S., Nakayama K. Degradation of p27(Kip1) at the G0-G1 transition mediated by a Skp2-independent ubiquitination pathway. J. Biol. Chem. 2001, 276:48937-48943.
202. Malek N.P., Sundberg H., McGrew S., Nakayama K., Kyriakides T.R., Roberts J.M. A mouse knock-in model exposes sequential proteolytic pathways that regulate p27Kip1 in G1 and S phase. Nature 2001, 413:323-327.
203. Fujita N., Sato S., Tsuruo T. Phosphorylation of p27Kip1 at threonine 198 by p90 ribosomal protein S6 kinases promotes its binding to 14-3-3 and cytoplasmic localization. J. Biol. Chem. 2003, 278:49254-49260.
204. Medema R.H., Kops G.J., Bos J.L., Burgering B.M. AFX-like Forkhead transcription factors mediate cell-cycle regulation by Ras and PKB through p27kip1. Nature 2000, 404:782-787.
205. Stahl M., Dijkers P.F., Kops G.J., Lens S.M., Coffer P.J., Burgering B.M., et al. The Forkhead transcription factor FoxO regulates transcription of p27Kip1 and Bim in response to IL-2. J. Immunol. 2002, 168:5024-5031.
206. Kops G.J., de Ruiter N.D., De Vries-Smits A.M., Powell D.R., Bos J.L., Burgering B.M. Direct control of the Forkhead transcription factor AFX by protein kinase B. Nature 1999, 398:630-634.
207. Rena G., Guo S., Cichy S.C., Unterman T.G., Cohen P. Phosphorylation of the transcription factor forkhead family member FKHR by protein kinase B. J. Biol. Chem. 1999, 274:17179-17183.
208. Serrano M., Hannon G.J., Beach D. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature 1993, 366:704-707.
209. Hannon G.J., Beach D. p15INK4B is a potential effector of TGF-beta-induced cell cycle arrest. Nature 1994, 371:257-261.
210. Chen P.L., Scully P., Shew J.Y., Wang J.Y., Lee W.H. Phosphorylation of the retinoblastoma gene product is modulated during the cell cycle and cellular differentiation. Cell 1989, 58:1193-1198.
211. Bartek J., Bartkova J., Lukas J. The retinoblastoma protein pathway in cell cycle control and cancer. Exp. Cell Res. 1997, 237:1-6.
212. Magae J., Wu C.L., Illenye S., Harlow E., Heintz N.H. Nuclear localization of DP and E2F transcription factors by heterodimeric partners and retinoblastoma protein family members. J. Cell Sci. 1996, 109(Pt 7):1717-1726.
213. Pierce A.M., Schneider-Broussard R., Philhower J.L., Johnson D.G. Differential activities of E2F family members: unique functions in regulating transcription. Mol. Carcinog. 1998, 22:190-198.
214. Yamasaki L. Balancing proliferation and apoptosis in vivo: the Goldilocks theory of E2F/DP action. Biochim. Biophys. Acta 1999, 1423:M9-15.
215. Campanero M.R., Armstrong M., Flemington E. Distinct cellular factors regulate the c-myb promoter through its E2F element. Mol. Cell Biol. 1999, 19:8442-8450.
216. Tamrakar S., Rubin E., Ludlow J.W. Role of pRB dephosphorylation in cell cycle regulation. Front Biosci. 2000, 5:D121-137.
217. Brehm A., Miska E.A., McCance D.J., Reid J.L., Bannister A.J., Kouzarides T. Retinoblastoma protein recruits histone deacetylase to repress transcription. Nature 1998, 391:597-601.
218. Magnaghi-Jaulin L., Groisman R., Naguibneva I., Robin P., Lorain S., Le Villain J.P., et al. Retinoblastoma protein represses transcription by recruiting a histone deacetylase. Nature 1998, 391:601-605.
219. Korenjak M., Taylor-Harding B., Binne U.K., Satterlee J.S., Stevaux O., Aasland R., et al. Native E2F/RBF complexes contain Myb-interacting proteins and repress transcription of developmentally controlled E2F target genes. Cell 2004, 119:181-193.
220. Lee H., Ohno K., Voskoboynik Y., Ragusano L., Martinez A., Dimova D.K. Drosophila RB proteins repress differentiation-specific genes via two different mechanisms. Mol. Cell Biol. 2010, 30:2563-2577.
221. Hoffmann I., Draetta G., Karsenti E. Activation of the phosphatase activity of human cdc25A by a cdk2-cyclin E dependent phosphorylation at the G1/S transition. EMBO J. 1994, 13:4302-4310.
222. Hassepass I., Voit R., Hoffmann I. Phosphorylation at serine 75 is required for UV-mediated degradation of human Cdc25A phosphatase at the S-phase checkpoint. J. Biol. Chem. 2003, 278:29824-29829.
223. Galaktionov K., Chen X., Beach D. Cdc25 cell-cycle phosphatase as a target of c-myc. Nature 1996, 382:511-517.
224. Nishitani H., Lygerou Z. Control of DNA replication licensing in a cell cycle. Genes Cells 2002, 7:523-534.
225. Diffley J.F., Cocker J.H., Dowell S.J., Rowley A. Two steps in the assembly of complexes at yeast replication origins in vivo. Cell 1994, 78:303-316.
226. Drury L.S., Diffley J.F. Factors affecting the diversity of DNA replication licensing control in eukaryotes. Curr. Biol. 2009, 19:530-535.
227. Dutta A., Bell S.P. Initiation of DNA replication in eukaryotic cells. Annu. Rev. Cell Dev. Biol. 1997, 13:293-332.
228. Tsakraklides V., Bell S.P. Dynamics of pre-replicative complex assembly. J. Biol. Chem. 2010, 285:9437-9443.
229. Kelly T.J., Martin G.S., Forsburg S.L., Stephen R.J., Russo A., Nurse P. The fission yeast cdc18+ gene product couples S phase to START and mitosis. Cell 1993, 74:371-382.
230. Nishitani H., Lygerou Z., Nishimoto T., Nurse P. The Cdt1 protein is required to license DNA for replication in fission yeast. Nature 2000, 404:625-628.
231. Lee J.K., Hurwitz J. Processive DNA helicase activity of the minichromosome maintenance proteins 4, 6, and 7 complex requires forked DNA structures. Proc. Natl. Acad. Sci. USA 2001, 98:54-59.
232. De Marco V., Gillespie P.J., Li A., Karantzelis N., Christodoulou E., Klompmaker R., et al. Quaternary structure of the human Cdt1-Geminin complex regulates DNA replication licensing. Proc. Natl. Acad. Sci. USA 2009, 106:19807-19812.
233. McGarry T.J., Kirschner M.W. Geminin, an inhibitor of DNA replication, is degraded during mitosis. Cell 1998, 93:1043-1053.
234. DePamphilis M.L. Cell cycle dependent regulation of the origin recognition complex. Cell Cycle 2005, 4:70-79.
235. McNairn A.J., Okuno Y., Misteli T., Gilbert D.M. Chinese hamster ORC subunits dynamically associate with chromatin throughout the cell-cycle. Exp. Cell Res. 2005, 308:345-356.
236. Masai H., Sato N., Takeda T., Arai K. CDC7 kinase complex as a molecular switch for DNA replication. Front Biosci. 1999, 4:D834-840.
237. Mimura S., Masuda T., Matsui T., Takisawa H. Central role for cdc45 in establishing an initiation complex of DNA replication in Xenopus egg extracts. Genes Cells 2000, 5:439-452.
238. Walter J., Newport J. Initiation of eukaryotic DNA replication: origin unwinding and sequential chromatin association of Cdc45, RPA, and DNA polymerase alpha. Mol. Cell 2000, 5:617-627.
239. Zou L., Stillman B. Assembly of a complex containing Cdc45p, replication protein A, and Mcm2p at replication origins controlled by S-phase cyclin-dependent kinases and Cdc7p-Dbf4p kinase. Mol. Cell Biol. 2000, 20:3086-3096.
240. Takisawa H., Mimura S., Kubota Y. Eukaryotic DNA replication: from pre-replication complex to initiation complex. Curr. Opin. Cell Biol. 2000, 12:690-696.
241. Furstenthal L., Swanson C., Kaiser B.K., Eldridge A.G., Jackson P.K. Triggering ubiquitination of a CDK inhibitor at origins of DNA replication. Nat. Cell Biol. 2001, 3:715-722.
242. Masui Y., Markert C.L. Cytoplasmic control of nuclear behavior during meiotic maturation of frog oocytes. J. Exp. Zool. 1971, 177:129-145.
243. Dulic V., Stein G.H., Far D.F., Reed S.I. Nuclear accumulation of p21Cip1 at the onset of mitosis: a role at the G2/M-phase transition. Mol. Cell Biol. 1998, 18:546-557.
244. Niculescu A.B., Chen X., Smeets M., Hengst L., Prives C., Reed S.I. Effects of p21(Cip1/Waf1) at both the G1/S and the G2/M cell cycle transitions: pRb is a critical determinant in blocking DNA replication and in preventing endoreduplication. Mol. Cell Biol. 1998, 18:629-643.
245. Sadhu K., Reed S.I., Richardson H., Russell P. Human homolog of fission yeast cdc25 mitotic inducer is predominantly expressed in G2. Proc. Natl. Acad. Sci. USA 1990, 87:5139-5143.
246. Strausfeld U., Fernandez A., Capony J.P., Girard F., Lautredou N., Derancourt J., et al. Activation of p34cdc2 protein kinase by microinjection of human cdc25C into mammalian cells. Requirement for prior phosphorylation of cdc25C by p34cdc2 on sites phosphorylated at mitosis. J. Biol. Chem. 1994, 269:5989-6000.
247. Timofeev O., Cizmecioglu O., Settele F., Kempf T., Hoffmann I. Cdc25 phosphatases are required for timely assembly of CDK1-cyclin B at the G2/M transition. J. Biol. Chem. 2010, 285:16978-16990.
248. Hoffmann I., Clarke P.R., Marcote M.J., Karsenti E., Draetta G. Phosphorylation and activation of human cdc25-C by cdc2-cyclin B and its involvement in the self-amplification of MPF at mitosis. EMBO J. 1993, 12:53-63.
249. Parker L.L., Sylvestre P.J., Byrnes M.J., Liu F., Piwnica-Worms H. Identification of a 95-kDa WEE1-like tyrosine kinase in HeLa cells. Proc. Natl. Acad. Sci. USA 1995, 92:9638-9642.
250. Potapova T.A., Daum J.R., Byrd K.S., Gorbsky G.J. Fine tuning the cell cycle: activation of the Cdk1 inhibitory phosphorylation pathway during mitotic exit. Mol. Biol. Cell. 2009, 20:1737-1748.
251. Nasmyth K., Peters J.M., Uhlmann F. Splitting the chromosome: cutting the ties that bind sister chromatids. Science 2000, 288:1379-1385.
252. Shimada K., Gasser S.M. The origin recognition complex functions in sister-chromatid cohesion in Saccharomyces cerevisiae. Cell 2007, 128:85-99.
253. Uhlmann F., Wernic D., Poupart M.A., Koonin E.V., Nasmyth K. Cleavage of cohesin by the CD clan protease separin triggers anaphase in yeast. Cell 2000, 103:375-386.
254. Papi M., Berdougo E., Randall C.L., Ganguly S., Jallepalli P.V. Multiple roles for separase auto-cleavage during the G2/M transition. Nat. Cell Biol. 2005, 7:1029-1035.
255. Waizenegger I.C., Hauf S., Meinke A., Peters J.M. Two distinct pathways remove mammalian cohesin from chromosome arms in prophase and from centromeres in anaphase. Cell 2000, 103:399-410.
256. Stemmann O., Zou H., Gerber S.A., Gygi S.P., Kirschner M.W. Dual inhibition of sister chromatid separation at metaphase. Cell 2001, 107:715-726.
257. Zachariae W., Nasmyth K. Whose end is destruction: cell division and the anaphase-promoting complex. Genes Dev. 1999, 13:2039-2058.
258. Marangos P., Carroll J. Securin regulates entry into M-phase by modulating the stability of cyclin B. Nat. Cell Biol. 2008, 10:445-451.
259. Donaldson M.M., Tavares A.A., Hagan I.M., Nigg E.A., Glover D.M. The mitotic roles of Polo-like kinase. J. Cell Sci. 2001, 114:2357-2358.
260. Toyoshima-Morimoto F., Taniguchi E., Shinya N., Iwamatsu A., Nishida E. Polo-like kinase 1 phosphorylates cyclin B1 and targets it to the nucleus during prophase. Nature 2001, 410:215-220.
261. Tsvetkov L., Xu X., Li J., Stern D.F. Polo-like kinase 1 and Chk2 interact and co-localize to centrosomes and the midbody. J. Biol. Chem. 2003, 278:8468-8475.
262. 3-regulated human keratinocyte proliferation and differentiation: basic studies and their clinical application. J. Nutr. 1995, 125:1709S-1714S.
263. 3 effects on cell cycle. J. Dermatol. Sci. 1998, 17:108-114.
264. 3 reverses the G1 block but not differentiation of HL60 cells. Leukemia 1998, 12:1256-1265.
265. Reitsma P.H., Rothberg P.G., Astrin S.M., Trial J., Bar-Shavit Z., Hall A., et al. Regulation of myc gene expression in HL-60 leukaemia cells by a vitamin D metabolite. Nature 1983, 306:492-494.
266. Studzinski G.P. Oncogenes, growth, and the cell cycle: an overview. Cell Tissue Kinet. 1989, 22:405-424.
267. 3-treated HL60 cells. Cancer Res. 1997, 57:2851-2855.
268. 3 reduces c-Myc expression, inhibiting proliferation and causing G1 accumulation in C4-2 prostate cancer cells. Endocrinology 2009, 150:2046-2054.
269. Urano T., Hosoi T., Shiraki M., Toyoshima H., Ouchi Y., Inoue S. Possible involvement of the p57(Kip2) gene in bone metabolism. Biochem. Biophys. Res. Commun. 2000, 269:422-426.
270. Steinman R.A., Hoffman B., Iro A., Guillouf C., Liebermann D.A., el-Houseini M.E. Induction of p21 (WAF-1/CIP1) during differentiation. Oncogene 1994, 9:3389-3396.
271. Parker S.B., Eichele G., Zhang P., Rawls A., Sands A.T., Bradley A., et al. p53-independent expression of p21Cip1 in muscle and other terminally differentiating cells. Science 1995, 267:1024-1027.
272. Deng C., Zhang P., Harper J.W., Elledge S.J., Leder P. Mice lacking p21CIP1/WAF1 undergo normal development, but are defective in G1 checkpoint control. Cell 1995, 82:675-684.
273. Missero C., Di Cunto F., Kiyokawa H., Koff A., Dotto G.P. The absence of p21Cip1/WAF1 alters keratinocyte growth and differentiation and promotes ras-tumor progression. Genes Dev. 1996, 10:3065-3075.
274. Harvat B.L., Wang A., Seth P., Jetten A.M. Up-regulation of p27Kip1, p21WAF1/Cip1 and p16Ink4a is associated with, but not sufficient for, induction of squamous differentiation. J. Cell Sci. 1998, 111(Pt 9):1185-1196.
275. 3) inhibits the growth of squamous cell carcinoma and down-modulates p21(Waf1/Cip1) in vitro and in vivo. Cancer Res. 1999, 59:2644-2649.
276. 3 in human prostate cancer cell line LNCaP involves reduction of cyclin-dependent kinase 2 activity and persistent G1 accumulation. Endocrinology 1998, 139:1197-1207.
277. 3 growth inhibition in the LNCaP prostate cancer cell line through p21/WAF1. J. Urol. 2001, 165:1319-1324.
278. 3 are mediated by increased levels of p21 in the prostatic carcinoma cell line ALVA-31. Cancer Res. 2001, 61:7122-7129.
279. 3 and its analogue, EB1089, in human breast cancer cells. Oncogene 1997, 15:1555-1563.
280. 3 on the cell cycle genes, cyclin D1, p21 and p27 in MCF-7 cells. Mol. Cell Endocrinol. 1998, 142:57-65.
281. 3 on the G1-S phase-controlling machinery. Mol. Endocrinol. 2001, 15:1370-1380.
282. Cozzolino M., Lu Y., Finch J., Slatopolsky E., Dusso A.S. p21WAF1 and TGF-alpha mediate parathyroid growth arrest by vitamin D and high calcium. Kidney Int. 2001, 60:2109-2117.
283. Waga S., Li R., Stillman B. p53-induced p21 controls DNA replication. Leukemia 1997, 11(Suppl. 3):321-323.
284. Kawa S., Nikaido T., Aoki Y., Zhai Y., Kumagai T., Furihata K., et al. Vitamin D analogues up-regulate p21 and p27 during growth inhibition of pancreatic cancer cell lines. Br. J. Cancer 1997, 76:884-889.
285. Das D., Pintucci G., Stern A. MAPK-dependent expression of p21(WAF) and p27(kip1) in PMA-induced differentiation of HL60 cells. FEBS Lett. 2000, 472:50-52.
286. 3 induces elevated expression of the cell cycle-regulating genes P21 and P27 in squamous carcinoma cell lines of the head and neck. Acta Otolaryngol. 2001, 121:103-109.
287. 3 induces differentiation of a retinoic acid-resistant acute promyelocytic leukemia cell line (UF-1) associated with expression of p21(WAF1/CIP1) and p27(KIP1). Blood 1999, 93:2225-2233.
288. 3 analogue EB1089 in head and neck squamous cell carcinoma. J. Natl. Cancer Inst. 2001, 93:745-753.
289. 3 in primary, but not immortalized, mouse embryonic fibroblasts. J. Biol. Chem. 2002, 277:37301-37306.
290. LaBaer J., Garrett M.D., Stevenson L.F., Slingerland J.M., Sandhu C., Chou H.S., et al. New functional activities for the p21 family of CDK inhibitors. Genes Dev. 1997, 11:847-862.
291. Cheng M., Olivier P., Diehl J.A., Fero M., Roussel M.F., Roberts J.M., et al. The p21(Cip1) and p27(Kip1) CDK "inhibitors" are essential activators of cyclin D-dependent kinases in murine fibroblasts. EMBO J. 1999, 18:1571-1583.
292. Polyak K., Lee M.H., Erdjument-Bromage H., Koff A., Roberts J.M., Tempst P., et al. Cloning of p27Kip1, a cyclin-dependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals. Cell 1994, 78:59-66.
293. Reynisdottir I., Polyak K., Iavarone A., Massague J. Kip/Cip and Ink4 Cdk inhibitors cooperate to induce cell cycle arrest in response to TGF-beta. Genes Dev. 1995, 9:1831-1845.
294. Vlach J., Hennecke S., Amati B. Phosphorylation-dependent degradation of the cyclin-dependent kinase inhibitor p27. EMBO J. 1997, 16:5334-5344.
295. Montagnoli A., Fiore F., Eytan E., Carrano A.C., Draetta G.F., Hershko A., et al. Ubiquitination of p27 is regulated by Cdk-dependent phosphorylation and trimeric complex formation. Genes Dev. 1999, 13:1181-1189.
296. Spruck C., Strohmaier H., Watson M., Smith A.P., Ryan A., Krek T.W., et al. A CDK-independent function of mammalian Cks1: targeting of SCF(Skp2) to the CDK inhibitor p27Kip1. Mol. Cell 2001, 7:639-650.
297. Lin R., Wang T.T., Miller W.H., White J.H. Inhibition of F-Box protein p45(SKP2) expression and stabilization of cyclin-dependent kinase inhibitor p27(KIP1) in vitamin D analog-treated cancer cells. Endocrinology 2003, 144:749-753.
298. 3 in ovarian cancer cells mediated through down-regulation of cyclin E/cyclin-dependent kinase 2 and Skp1-Cullin-F-box protein/Skp2 ubiquitin ligase. J. Biol. Chem. 2004, 279:25260-25267.
299. Luo W., Chen Y., Liu M., Du K., Zheng G., Cai T., et al. EB1089 induces Skp2-dependent p27 accumulation, leading to cell growth inhibition and cell cycle G1 phase arrest in human hepatoma cells. Cancer Invest. 2009, 27:29-37.
300. Sitry D., Seeliger M.A., Ko T.K., Ganoth D., Breward S.E., Itzhaki L.S., et al. Three different binding sites of Cks1 are required for p27-ubiquitin ligation. J. Biol. Chem. 2002, 277:42233-42240.
301. Tapia J.C., Bolanos-Garcia V.M., Sayed M., Allende C.C., Allende J.E. Cell cycle regulatory protein p27KIP1 is a substrate and interacts with the protein kinase CK2. J. Cell Biochem. 2004, 91:865-879.
302. Grimmler M., Wang Y., Mund T., Cilensek Z., Keidel E.M., Waddell M.B., et al. Cdk-inhibitory activity and stability of p27Kip1 are directly regulated by oncogenic tyrosine kinases. Cell 2007, 128:269-280.
303. Cuesta R., Martinez-Sanchez A., Gebauer F. miR-181a regulates cap-dependent translation of p27(kip1) mRNA in myeloid cells. Mol. Cell Biol. 2009, 29:2841-2851.
304. Juan G., Li X., Darzynkiewicz Z. Phosphorylation of retinoblastoma protein assayed in individual HL-60 cells during their proliferation and differentiation. Exp. Cell Res. 1998, 244:83-92.
305. Clarke A.R., Maandag E.R., van Roon M., van der Lugt N.M., van der Valk M., Hooper M.L., et al. Requirement for a functional Rb-1 gene in murine development. Nature 1992, 359:328-330.
306. Lee E.Y., Chang C.Y., Hu N., Wang Y.C., Lai C.C., Herrup K., et al. Mice deficient for Rb are nonviable and show defects in neurogenesis and haematopoiesis. Nature 1992, 359:288-294.
307. Condorelli G.L., Testa U., Valtieri M., Vitelli L., De Luca A., Barberi T., et al. Modulation of retinoblastoma gene in normal adult hematopoiesis: peak expression and functional role in advanced erythroid differentiation. Proc. Natl. Acad. Sci. USA 1995, 92:4808-4812.
308. Johansen L.M., Iwama A., Lodie T.A., Sasaki K., Felsher D.W., Golub T.R., et al. c-Myc is a critical target for C/EBPalpha in granulopoiesis. Mol. Cell Biol. 2001, 21:3789-3806.
309. Watanabe T., Sariban E., Mitchell T., Kufe D. Human c-myc and N-ras expression during induction of HL-60 cellular differentiation. Biochem. Biophys. Res. Commun. 1985, 126:999-1005.
310. Brelvi Z.S., Studzinski G.P. Changes in the expression of oncogenes encoding nuclear phosphoproteins but not c-Ha-ras have a relationship to monocytic differentiation of HL 60 cells. J. Cell Biol. 1986, 102:2234-2243.
311. Wilson A.J., Velcich A., Arango D., Kurland A.R., Shenoy S.M., Pezo R.C., et al. Novel detection and differential utilization of a c-myc transcriptional block in colon cancer chemoprevention. Cancer Res. 2002, 62:6006-6010.
312. 3 analogs and their superagonistic action. J. Steroid Biochem. Mol. Biol. 2010, 121:417-419.
313. 3 inhibits growth of VCaP prostate cancer cells despite inducing the growth-promoting TMPRSS2:ERG gene fusion. Endocrinology 2010, 151:1409-1417.
314. Dang C.V., Resar L.M., Emison E., Kim S., Li Q., Prescott J.E., et al. Function of the c-Myc oncogenic transcription factor. Exp. Cell Res. 1999, 253:63-77.
315. Nesbit C.E., Tersak J.M., Prochownik E.V. MYC oncogenes and human neoplastic disease. Oncogene 1999, 18:3004-3016.
316. Brelvi Z.S., Studzinski G.P. Coordinate expression of c-myc, c-myb, and histone H4 genes in reversibly differentiating HL 60 cells. J. Cell Physiol. 1987, 131:43-49.
317. Coller H.A., Grandori C., Tamayo P., Colbert T., Lander E.S., Eisenman R.N., et al. Expression analysis with oligonucleotide microarrays reveals that MYC regulates genes involved in growth, cell cycle, signaling, and adhesion. Proc. Natl. Acad. Sci. USA 2000, 97:3260-3265.
318. Gartel A.L., Ye X., Goufman E., Shianov P., Hay N., Najmabadi F., et al. Myc represses the p21(WAF1/CIP1) promoter and interacts with Sp1/Sp3. Proc. Natl. Acad. Sci. USA 2001, 98:4510-4515.
319. Gartel A.L., Shchors K. Mechanisms of c-myc-mediated transcriptional repression of growth arrest genes. Exp. Cell Res. 2003, 283:17-21.
320. 3 regulation of c-myc protooncogene transcription. Possible involvement of protein kinase C. J. Biol. Chem. 1989, 264:19710-19715.
321. 3 regulation of c-myc during HL-60 cell differentiation and the involvement of HOXB4. J. Biol. Chem. 1999, 274:8437-8444.
322. 3 inhibition of c-myc expression. J. Endocrinol. 2001, 169:153-159.
323. Shen W.F., Largman C., Lowney P., Corral J.C., Detmer K., Hauser C.A., et al. Lineage-restricted expression of homeobox-containing genes in human hematopoietic cell lines. Proc. Natl. Acad. Sci. USA 1989, 86:8536-8540.
324. Celetti A., Barba P., Cillo C., Rotoli B., Boncinelli E., Magli M.C. Characteristic patterns of HOX gene expression in different types of human leukemia. Int. J. Cancer 1993, 53:237-244.
325. Magli M.C., Largman C., Lawrence H.J. Effects of HOX homeobox genes in blood cell differentiation. J. Cell Physiol. 1997, 173:168-177.
326. Lill M.C., Fuller J.F., Herzig R., Crooks G.M., Gasson J.C. The role of the homeobox gene, HOX B7, in human myelomonocytic differentiation. Blood 1995, 85:692-697.
327. 3 induction in myeloid leukemic cells. Mol. Cell Biol. 1998, 18:1911-1918.
328. Myrthue A., Rademacher B.L., Pittsenbarger J., Kutyba-Brooks B., Gantner
329. 3 promotes the differentiation of colon carcinoma cells by the induction of E-cadherin and the inhibition of beta-catenin signaling. J. Cell Biol. 2001, 154:369-387.
330. Sansom O.J., Meniel V.S., Muncan V., Phesse T.J., Wilkins J.A., Reed K.R., et al. Myc deletion rescues Apc deficiency in the small intestine. Nature 2007, 446:676-679.
331. 3 in the murine myelomonocytic leukemia cell line WEHI-3. Cancer Res. 1986, 46:6316-6321.
332. 3. Cell Prolif. 1994, 27:37-46.
333. 3-induced retardation of the G2/M traverse is associated with decreased levels of p34(cdc2) in HL60 cells. J. Cell Biochem. 1999, 75:226-234.
334. 3 and malignant melanoma: the presence of receptors and inhibition of cell growth in culture. Endocrinology 1981, 108:1083-1086.
335. Damera G., Fogle H.W., Lim P., Goncharova E.A., Zhao H., Banerjee A., et al. Vitamin D inhibits growth of human airway smooth muscle cells through growth factor-induced phosphorylation of retinoblastoma protein and checkpoint kinase 1. Br. J. Pharmacol. 2009, 158:1429-1441.
336. Liu W., Asa S.L., Fantus I.G., Walfish P.G., Ezzat S. Vitamin D arrests thyroid carcinoma cell growth and induces p27 dephosphorylation and accumulation through PTEN/Akt-dependent and -independent pathways. Am. J. Pathol. 2002, 160:511-519.
337. Liu W., Asa S.L., Ezzat S. Vitamin D and its analog EB1089 induce p27 accumulation and diminish association of p27 with Skp2 independent of PTEN in pituitary corticotroph cells. Brain Pathol. 2002, 12:412-419.
338. 3-resistant variant can be sensitized by TPA. J. Steroid Biochem. Mol. Biol. 2003, 84:199-209.
339. 3 protects HL60 cells against apoptosis but down-regulates the expression of the bcl-2 gene. Exp. Cell Res. 1993, 209:367-374.
340. 3 is associated with increased mitochondrial MCL-1 and RAF-1 proteins and reduced release of cytochrome c. Exp. Cell Res. 1997, 235:210-217.
341. Marcinkowska E., Chrobak A., Wiedlocha A. Evading apoptosis by calcitriol-differentiated human leukemic HL-60 cells is not mediated by changes in CD95 receptor system but by increased sensitivity of these cells to insulin. Exp. Cell Res. 2001, 270:119-127.
342. Wang X., Patel R., Studzinski G.P. hKSR-2, a vitamin D-regulated gene, inhibits apoptosis in arabinocytosine-treated HL60 leukemia cells. Mol. Cancer Ther. 2008, 7:2798-2806.
343. Hansen C.M., Hansen D., Holm P.K., Binderup L. Vitamin D compounds exert anti-apoptotic effects in human osteosarcoma cells in vitro. J. Steroid Biochem. Mol. Biol. 2001, 77:1-11.
344. 3 membrane-initiated calcium signaling modulates exocytosis and cell survival. J. Steroid Biochem. Mol. Biol. 2007, 103:457-461.
345. 3 and its low-calcemic analogues on staurosporine-induced apoptosis. Pharmacol. Rep. 2007, 59:393-401.
346. 3 in primary human keratinocytes. J. Cell Biochem. 2004, 93:951-967.
347. 3 and analogs through the ligand binding domain of the vitamin D receptor in osteoblasts and osteocytes. Mediation by Src, phosphatidylinositol 3-, and JNK kinases. J. Biol. Chem. 2005, 280:14130-14137.
348. Langberg M., Rotem C., Fenig E., Koren R., Ravid A. Vitamin D protects keratinocytes from deleterious effects of ionizing radiation. Br. J. Dermatol. 2009, 160:151-161.
349. Kajta M., Makarewicz D., Zieminska E., Jantas D., Domin H., Lason W., et al. Neuroprotection by co-treatment and post-treating with calcitriol following the ischemic and excitotoxic insult in vivo and in vitro. Neurochem. Int. 2009, 55:265-274.
350. 3 inhibits cell proliferation by promoting cell cycle arrest without inducing apoptosis and modifies cell morphology of mesenchymal multipotent cells. J. Steroid Biochem. Mol. Biol. 2010, 119:73-83.
351. 3 of a deoxycytidine kinase-deficient variant of human leukemia HL60 cells. Exp. Cell Res. 1992, 203:244-250.
352. 3-resistant human chronic myelogenous leukemia cell line. Blood 1994, 84:4283-4294.
353. 3 analogue and anti-activator protein 1 retinoid. Br. J. Cancer 1999, 79:101-107.
354. 3 analogs and paclitaxel on the growth of MCF-7 breast cancer cells in vivo. Breast Cancer Res. Treat 1999, 53:113-120.
355. Danilenko M., Wang X., Studzinski G.P. Carnosic acid and promotion of monocytic differentiation of HL60-G cells initiated by other agents. J. Natl. Cancer Inst. 2001, 93:1224-1233.
356. 3-induced apoptosis in association with increased mitogen-activated protein kinase kinase kinase 1 (MEKK-1) expression. Mol. Cancer Ther. 2002, 1:821-829.
357. Ahmed S., Johnson C.S., Rueger R.M., Trump D.L. Calcitriol (1,25-dihydroxycholecalciferol) potentiates activity of mitoxantrone/dexamethasone in an androgen independent prostate cancer model. J. Urol. 2002, 168:756-761.
358. 3 and its analogs. Exp. Cell Res. 2004, 298:339-358.
359. 3 and a non-steroid anti-inflammatory drug is highly effective in suppressing prostate cancer cell line (LNCaP) growth. Anticancer Res. 2005, 25:3425-3429.
360. 3 enhances monocytic differentiation along with becoming resistant to apoptosis by induction of cytoplasmic p21CIP1. Int. J. Oncol. 2005, 27:893-900.
361. 3 derivatives and rosemary preparations in a mouse model of myeloid leukemia. Int. J. Cancer 2006, 118:3012-3021.
362. Hewison M., Barker S., Brennan A., Katz D.R., O'Riordan J.L. Modulation of myelomonocytic U937 cells by vitamin D metabolites. Bone Miner. 1989, 5:323-333.
363. 3 and GM-CSF. Leuk. Res. 1992, 16:427-434.
364. 2 (paricalcitol): effects on clonal proliferation, differentiation, and apoptosis in human leukemic cell lines. J. Cancer Res. Clin. Oncol. 2003, 129:35-42.
365. Rius C., Aller P. Modulation of ornithine decarboxylase gene transcript levels by differentiation inducers in human promyelocytic leukemia HL60 cells. Cell Differ. Dev. 1989, 28:39-46.
366. 3: comparison with the maturation of normal monocytic and granulocytic bone marrow cells. J. Leukoc. Biol. 1995, 58:547-555.
367. Yam L.T., Li C.Y., Crosby W.H. Cytochemical identification of monocytes and granulocytes. Am. J. Clin. Pathol. 1971, 55:283-290.
368. 3 analogs have potent antitumor activity. J. Steroid Biochem. Mol. Biol. 2008, 112:151-156.
369. Olsson I., Gullberg U., Ivhed I., Nilsson K. Induction of differentiation of the human histiocytic lymphoma cell line U-937 by 1 alpha,25-dihydroxycholecalciferol. Cancer Res. 1983, 43:5862-5867.
370. Blair O.C., Carbone R., Sartorelli A.C. Differentiation of HL-60 promyelocytic leukemia cells monitored by flow cytometric measurement of nitro blue tetrazolium (NBT) reduction. Cytometry 1985, 6:54-61.
371. 3-induced monocyte antimycobacterial activity is regulated by phosphatidylinositol 3-kinase and mediated by the NADPH-dependent phagocyte oxidase. J. Biol. Chem. 2001, 276:35482-35493.
372. 3 analogues: disassociation of their prominent antileukemic effects from their lack of calcium modulation. Cancer Res. 2001, 61:3361-3368.
373. Gum J.R., Kam W.K., Byrd J.C., Hicks J.W., Sleisenger M.H., Kim Y.S. Effects of sodium butyrate on human colonic adenocarcinoma cells. Induction of placental-like alkaline phosphatase. J. Biol. Chem. 1987, 262:1092-1097.
374. Giuliano A.R., Franceschi R.T., Wood R.J. Characterization of the vitamin D receptor from the Caco-2 human colon carcinoma cell line: effect of cellular differentiation. Arch. Biochem. Biophys. 1991, 285:261-269.
375. Gaschott T., Stein J. Short-chain fatty acids and colon cancer cells: the vitamin D receptor-butyrate connection. Recent Results Cancer Res. 2003, 164:247-257.
376. Saini K., Steele G., Thomas P. Induction of carcinoembryonic-antigen-gene expression in human colorectal carcinoma by sodium butyrate. Biochem. J. 1990, 272:541-544.
377. Buras R.R., Shabahang M., Davoodi F., Schumaker L.M., Cullen K.J., Byers S., et al. The effect of extracellular calcium on colonocytes: evidence for differential responsiveness based upon degree of cell differentiation. Cell Prolif. 1995, 28:245-262.
378. Staal A., van Wijnen A.J., Birkenhager J.C., Pols H.A., Prahl J., DeLuca H., et al. Distinct conformations of vitamin D receptor/retinoid X receptor-alpha heterodimers are specified by dinucleotide differences in the vitamin D-responsive elements of the osteocalcin and osteopontin genes. Mol. Endocrinol. 1996, 10:1444-1456.
379. Kommagani R., Whitlatch A., Leonard M.K., Kadakia M.P. p73 is essential for vitamin D-mediated osteoblastic differentiation. Cell Death Differ. 2010, 17:398-407.
380. 3 specific regulation of growth, morphology, and fibronectin in a human osteosarcoma cell line. J. Cell Physiol. 1985, 123:401-409.
381. 3-analogs on osteoblast-like cells and on in vitro bone resorption. J. Steroid Biochem. Mol. Biol. 1995, 55:337-346.
382. 3 and thyroid hormones. Cell Biol. Int. 2003, 27:459-468.
383. Pernalete N., Mori T., Nishii Y., Slatopolsky E., Brown A.J. The activity of 22-oxacalcitriol in osteoblast-like (ROS 17/2.8) cells. Endocrinology 1991, 129:778-784.
384. 3 (2MD) on osteoblastic cells. J. Steroid Biochem. Mol. Biol. 2008, 112:110-116.
385. 3 receptors and actions in human prostate cancer cell lines. Endocrinology 1993, 132:1952-1960.
386. Esquenet M., Swinnen J.V., Heyns W., Verhoeven G. Control of LNCaP proliferation and differentiation: actions and interactions of androgens, 1alpha,25-dihydroxycholecalciferol, all-trans retinoic acid, 9-cis retinoic acid, and phenylacetate. Prostate 1996, 28:182-194.
387. Hedlund T.E., Moffatt K.A., Uskokovic M.R., Miller G.J. Three synthetic vitamin D analogues induce prostate-specific acid phosphatase and prostate-specific antigen while inhibiting the growth of human prostate cancer cells in a vitamin D receptor-dependent fashion. Clin. Cancer Res. 1997, 3:1331-1338.
388. 3 analogue involves the induction of p21waf1, p27kip1 and E-cadherin. J. Mol. Endocrinol. 1997, 19:15-27.
389. Beer T.M., Garzotto M., Park B., Mori M., Myrthue A., Janeba N., et al. Effect of calcitriol on prostate-specific antigen in vitro and in humans. Clin. Cancer Res. 2006, 12:2812-2816.
390. Otto T., Rembrink K., Goepel M., Meyer-Schwickerath M., Rubben H. E-cadherin: a marker for differentiation and invasiveness in prostatic carcinoma. Urol. Res. 1993, 21:359-362.
391. 3 analogues: a novel class of potent inhibitors of proliferation and inducers of differentiation of human breast cancer cell lines. Cancer Res. 1995, 55:2822-2830.
392. 5 in T47D human breast cancer cells and its interaction with vitamin D receptors. Eur. J. Cancer 2000, 36:780-786.
393. 5. Int. J. Oncol. 2000, 16:65-73.
394. 3 and retinoic acid analogues induce differentiation in breast cancer cells with function- and cell-specific additive effects. Breast Cancer Res. Treat 2001, 67:157-168.
395. Pendas-Franco N., Gonzalez-Sancho J.M., Suarez Y., Aguilera O., Steinmeyer A., Gamallo C., et al. Vitamin D regulates the phenotype of human breast cancer cells. Differentiation 2007, 75:193-207.
396. Lanks K.W., Dorwin J.M., Papirmeister B. Increased rate of acetylcholinesterase synthesis in differentiating neuroblastoma cells. J. Cell Biol. 1974, 63:824-830.
397. 3 on LA-N-5 human neuroblastoma cells and its synergy with retinoic acid. J. Pediatr. Hematol. Oncol. 1995, 17:311-317.
398. 3 analogs inhibit growth and induce differentiation in LA-N-5 human neuroblastoma cells. Clin. Exp. Metastasis 1996, 14:239-245.
399. 3 hybrid analog QW1624F2-2 in human neuroblastoma. J. Cell Biochem. 2006, 97:198-206.
400. 3 and retinoic acid. Cancer Res. 1985, 45:1474-1478.
401. Mason R.S., Pryke A.M., Ranson M., Thomas H.E., Posen S. Human melanoma cells: functional modulation by calciotropic hormones. J. Invest. Dermatol. 1988, 90:834-840.
402. 3 stimulates differentiation of squamous carcinoma cell line in the raft culture. Anticancer Res. 1996, 16:337-347.
403. Rice R.H., Green H. Relation of protein synthesis and transglutaminase activity to formation of the cross-linked envelope during terminal differentiation of the cultured human epidermal keratinocyte. J. Cell Biol. 1978, 76:705-711.
404. Murphy G.F., Flynn T.C., Rice R.H., Pinkus G.S. Involucrin expression in normal and neoplastic human skin: a marker for keratinocyte differentiation. J. Invest. Dermatol. 1984, 82:453-457.
405. Lee E., Jeon S.H., Yi J.Y., Jin Y.J., Son Y.S. Calcipotriol inhibits autocrine phosphorylation of EGF receptor in a calcium-dependent manner, a possible mechanism for its inhibition of cell proliferation and stimulation of cell differentiation. Biochem. Biophys. Res. Commun. 2001, 284:419-425.
406. 3, EB1089, and analog V on PTHrP production, PTHrP mRNA expression and cell growth in SCC 2/88. Anticancer Res. 2001, 21:3355-3363.
407. 3 on the morphologic and biochemical differentiation of cultured human epidermal keratinocytes grown in serum-free conditions. J. Invest. Dermatol. 1986, 86:709-714.
408. 3 and its analogues, tacalcitol, calcipotriol, and maxacalcitol on normal human keratinocyte proliferation and differentiation. J. Dermatol. Sci. 2003, 31:21-28.
409. Hawker N.P., Pennypacker S.D., Chang S.M., Bikle D.D. Regulation of human epidermal keratinocyte differentiation by the vitamin D receptor and its coactivators DRIP205, SRC2, and SRC3. J. Invest. Dermatol. 2007, 127:874-880.
410. Oda Y., Chalkley R.J., Burlingame A.L., Bikle D.D. The transcriptional coactivator DRIP/mediator complex is involved in vitamin D receptor function and regulates keratinocyte proliferation and differentiation. J. Invest. Dermatol. 2010, 130:2377-2388.
411. 3, novel P450scc product, stimulates differentiation and inhibits proliferation and NF-kappaB activity in human keratinocytes. J. Cell Physiol. 2010, 223:36-48.
412. Steven A.C., Steinert P.M. Protein composition of cornified cell envelopes of epidermal keratinocytes. J. Cell. Sci. 107 1994, (Pt 2):693-700.
413. 3 increases human cystatin A expression by inhibiting the Raf-1/MEK1/ERK signaling pathway of keratinocytes. Arch. Dermatol. Res. 2003, 295:80-87.
414. 3. J. Invest. Dermatol. 1993, 101:713-718.
415. Strohman R.C., Paterson B., Fluck R., Przybyla A. Cell fusion and terminal differentiation of myogenic cells in culture. J. Anim. Sci. 1974, 38:1103-1110.
416. 3. Biochim. Biophys. Acta. 1989, 1014:112-119.
417. 3 increases in vitro vascular calcification by modulating secretion of endogenous parathyroid hormone-related peptide. Circulation 1998, 98:1302-1306.
418. Shioi A., Katagi M., Okuno Y., Mori K., Jono S., Koyama H., et al. Induction of bone-type alkaline phosphatase in human vascular smooth muscle cells: roles of tumor necrosis factor-alpha and oncostatin M derived from macrophages. Circ. Res. 2002, 91:9-16.
419. Schwaller J., Koeffler H.P., Niklaus G., Loetscher P., Nagel S., Fey M.F., et al. Posttranscriptional stabilization underlies p53-independent induction of p21WAF1/CIP1/SDI1 in differentiating human leukemic cells. J. Clin. Invest. 1995, 95:973-979.
420. Munker R., Kobayashi T., Elstner E., Norman A.W., Uskokovic M., Zhang W., et al. A new series of vitamin D analogs is highly active for clonal inhibition, differentiation, and induction of WAF1 in myeloid leukemia. Blood 1996, 88:2201-2209.
421. Asada M., Yamada T., Ichijo H., Delia D., Miyazono K., Fukumuro K., et al. Apoptosis inhibitory activity of cytoplasmic p21(Cip1/WAF1) in monocytic differentiation. EMBO J. 1999, 18:1223-1234.
422. Asada M., Yamada T., Fukumuro K., Mizutani S. p21Cip1/WAF1 is important for differentiation and survival of U937 cells. Leukemia 1998, 12:1944-1950.
423. Asou H., Koike M., Elstner E., Cambell M., Le J., Uskokovic M.R., et al. 19-Nor vitamin-D analogs: a new class of potent inhibitors of proliferation and inducers of differentiation of human myeloid leukemia cell lines. Blood 1998, 92:2441-2449.
424. 3 on human B cell differentiation. J. Immunol. 2007, 179:1634-1647.
425. 3 analog, EB1089, on G1 cell cycle regulatory proteins in HL-60 cells. Int. J. Oncol. 2000, 16:315-320.
426. 3 and antioxidants. Cancer Biol. Ther. 2010, 10.
427. Yang E.S., Maiorino C.A., Roos B.A., Knight S.R., Burnstein K.L. Vitamin D-mediated growth inhibition of an androgen-ablated LNCaP cell line model of human prostate cancer. Mol. Cell Endocrinol. 2002, 186:69-79.
428. Yang E.S., Burnstein K.L. Vitamin D inhibits G1 to S progression in LNCaP prostate cancer cells through p27Kip1 stabilization and Cdk2 mislocalization to the cytoplasm. J. Biol. Chem. 2003, 278:46862-46868.
429. 3 and its analogues on induction of apoptosis in breast cancer cells. J. Steroid Biochem. Mol. Biol. 1996, 58:395-401.
430. 3-resistant variant. Endocrinology 1997, 138:4690-4698.
431. 3. Nucleic Acids Res. 2008, 36:121-132.
432. 3 in breast cancer cells. Cancer Res. 2000, 60:5578-5583.
433. 3. J. Biol. Chem. 2009, 284:8073-8082.
434. Lee H.J., Paul S., Atalla N., Thomas P.E., Lin X., Yang I., et al. Gemini vitamin D analogues inhibit estrogen receptor-positive and estrogen receptor-negative mammary tumorigenesis without hypercalcemic toxicity. Cancer Prev. Res. (Phila. Pa.) 2008, 1:476-484.
435. 3: a novel class of potent inhibitors of proliferation of human breast cell lines. Cancer Res. 1997, 57:4545-4550.
436. 3: a new class of potent inhibitors of proliferation of prostate, breast, and myeloid leukemic cells. Cancer Res. 1999, 59:4023-4029.
437. 5. Carcinogenesisa 2006, 27:551-559.
438. Flanagan L., Packman K., Juba B., O'Neill S., Tenniswood M., Welsh J. Efficacy of vitamin D compounds to modulate estrogen receptor negative breast cancer growth and invasion. J. Steroid Biochem. Mol. Biol. 2003, 84:181-192.
439. 2 (paricalcitol) inhibits the proliferation of human pancreatic cancer cells in vitro and in vivo. Cancer Biol. Ther. 2008, 7:430-436.
440. Galbiati F., Polastri L., Thorens B., Dupraz P., Fiorina P., Cavallaro U., et al. Molecular pathways involved in the antineoplastic effects of calcitriol on insulinoma cells. Endocrinology 2003, 144:1832-1841.
441. 3 analog (Ro 25-6760) inhibits human colon cancer in vitro via apoptosis. Int. J. Oncol. 1999, 14:979-985.
442. 3 analog induces a G1-phase arrest in CaCo-2 cells by inhibiting cdk2 and cdk6: roles of cyclin E, p21Waf1, and p27Kip1. Endocrinology 2000, 141:3931-3939.
443. Gaschott T., Wachtershauser A., Steinhilber D., Stein J. 1,25-Dihydroxycholecalciferol enhances butyrate-induced p21(Waf1/Cip1) expression. Biochem. Biophys. Res. Commun. 2001, 283:80-85.
444. Gaschott T., Steinmeyer A., Steinhilber D., Stein J. ZK 156718, a low calcemic, antiproliferative, and prodifferentiating vitamin D analog. Biochem. Biophys. Res. Commun. 2002, 290:504-509.
445. 3. Cancer Res. 2005, 65:493-498.
446. 3 analogs mediated by p27, Cdk2, cyclin E, and the retinoblastoma protein. Biochem. Pharmacol. 2003, 66:495-504.
447. Chung I., Wong M.K., Flynn G., Yu W.D., Johnson C.S., Trump D.L. Differential antiproliferative effects of calcitriol on tumor-derived and matrigel-derived endothelial cells. Cancer Res. 2006, 66:8565-8573.
448. 3 administration induces nuclear p27 accumulation, restores differentiation, and reduces tumor burden in a mouse model of metastatic follicular thyroid cancer. Endocrinology 2004, 145:5840-5846.
449. 3 on the proliferation of human neuroblastoma: role of cell cycle regulators and the Myc-Id2 pathway. Biochem. Pharmacol. 2003, 65:1943-1955.
450. 3 analogue, KH1060 in human neuroblastoma: induction of RAR-beta and p21(Cip1). Cancer Lett. 2003, 190:51-60.
451. Fujita N., Sato S., Katayama K., Tsuruo T. Akt-dependent phosphorylation of p27Kip1 promotes binding to 14-3-3 and cytoplasmic localization. J. Biol. Chem. 2002, 277:28706-28713.
452. 3. Exp. Cell Res. 2011, 317:117-130.